Abstract: The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.

Abstract: A bis-urea compound of general formula (IV): The compound is useful as a thermo-thickening agent in a non-polar liquid such as engine lubricating oil or thermosetting varnish. Also, a method for preparing the thermo-thickening compound. Further, a composition comprising the thermo-thickening compound and a non-polar liquid.

Abstract: A Sigma-Delta (??) modulator for converting an analog input signal having a frequency bandwidth around a variable center frequency f0 to a digital output signal at a sampling frequency fs. The ?? modulator comprises a quantizer (420) for generating the digital output signal and a loop filter for shaping the quantization noise. The loop filter comprises at least one subfilter (430, 410) centered around a frequency f0 and constant noise shaping coefficients (451, 452, 453). The ?? modulator further comprises a tunable delay element (455), a frequency adjuster (480) for adjusting the sampling frequency fs such that the normalized center frequency f0/fs is constant, and a delay adjuster (490) for adjusting the loop delay td implemented by the quantizer and the tunable delay element (455), such that the normalized loop delay td/Ts falls in a predetermined range [tmin, tmax], where Ts=1/fs.

Abstract: The invention relates to a miniature linear vibrotactile actuator comprising: a first element 14, 104 of generally cylindrical shape, comprising permanent magnets 15, 105 aligned so that two adjacent sides of two adjacent magnets 15, 105 have identical polarities; a second element 11, 101 defining a cylindrical cavity 12, 102 into which the first element 14, 104 is inserted with play so as to be able to slide therein in a sliding direction X2, the second element 11, 101 comprising coils 13, 103 of conductive wire having strands that extend perpendicularly to the sliding direction X2, in order to form magnetic force generators, and that are placed so as to be able to influence the first element 14, 104 electromagnetically; and means 25, 41, 125 for returning and guiding the first element 14, 104 toward an equilibrium position in the second element 11, 101, in which position a median plane P2 between two adjacent magnets substantially coincides with a median plane P1 of a facing force generator 111.

Abstract: The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.

Abstract: Disclosed is a method for the treatment, prevention and/or stabilisation of ARMD, Stargardt disease, pigmentary retinopathy and/or diabetic retinopathy, including the application of a 3-deoxyanthocyanidin of formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X? are as defined, with the condition that at least one of R1, R2, R3, R4 or R5 is a hydroxyl and at least one of R8, R9, R10 or R11 is a hydroxyl.

Abstract: The invention provides an in vitro method for determining the likelihood for a patient affected with a tumor to respond to a treatment with a pro-apoptotic peptide able to disrupt interaction between caspase 9 and PP2A, which method comprises determining expression level of at least each of VIM, MK167, TCF7L2, NEK2, BIRC5, MCL1, and PLK1 genes, in a biological sample of said patient.

Abstract: High dynamic range (HDR) images are generated on the basis of a plurality of images obtained by non-destructive reading of an image sensor, called NDRO images. An HDR image generation method includes: the determination of a criterion of desired quality for the HDR image; at least two non-destructive readings of the sensor delivering at least two successive NDRO images; the selection, as a function of the criterion of desired quality, of the first and of the last NDRO image to be used to generate the HDR image; the generation of the HDR image on the basis of information extracted from a series of successive NDRO images starting with the first and terminating with the last NDRO image to be used; the storage of a single image at one and the same time throughout the entire HDR generation phase.

Abstract: Disclosed is a method for processing asynchronous signals generated by a light sensor, the sensor having a matrix of pixels, the method including: —receiving the asynchronous signals, each signal being associated with a pixel in a group of pixels in the matrix, each signal including successive events issued by the associated pixel; —upon an occurrence of an event in one of the asynchronous signals, updating an integration value associated to the group by adding an additive value to the integration value; —if the integration value is greater than a predetermined threshold, generating an event in an outputted asynchronous signal.

Abstract: The present invention relates to a gene therapy vector which is useful in the treatment or prevention of hypertrophic cardiomyopathy in a subject in need thereof. The gene therapy vector of the invention comprises a nucleic acid sequence encoding a cardiac sarcomeric protein and a cardiomyocyte-specific promoter which is operably linked to said nucleic acid sequence. The invention furthermore relates to a cell which comprises the gene therapy vector. Pharmaceutical compositions which comprise the gene therapy vector and/or a cell comprising said vector are also provided. In another aspect, the invention relates to a method for treating or preventing hypertrophic cardiomyopathy in a subject by introducing the gene therapy vector of the invention into a subject in need of treatment.

Abstract: An in-ear stimulation system including a first device configured to be worn at least partially in a first ear canal of a subject and a second device configured to be worn at least partially in a second ear canal of the subject. Each of the first device and the second device includes: at least one in-ear active electrode configured to receive a bio-signal and at least one in-ear reference electrode configured to receive a bio-signal; at least one stimulation device configured for emitting at least one electrical or sensory stimulus; and an electronic system configured to detect at least one bio-signal pattern from the bio-signals measured from the electrodes.

Abstract: Disclosed is a force sensor, including: at least one measurement cell, each measurement cell being filled with a filling material in which at least one inclusion of a substance is embedded; for each cell, at least one light source arranged in order to illuminate the inclusion embedded in this cell; for each cell, a measurement system including at least one optical measurement point arranged in order to capture light originating from the inclusion embedded in this cell; for each cell, a unit arranged in order to convert optical signals originating from the measurement system of this cell to a signal representative of a force exerted on this cell, this signal being dependent on a movement of the inclusion embedded within the filling material of this cell.

Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

Abstract: The present invention relates to the combined use of antisense oligonucleotides and viral vectors for the treatment of Duchenne muscular dystrophy.

Abstract: Provided are tricyclo-DNA (tc-DNA) AON and methods employing tc-DNA AON for modifying splicing events that occur during pre-mRNA processing. Tricyclo-DNA (tc-DNA) AON are described that may be used to facilitate exon skipping or to mask intronic silencer sequences and/or terminal stein-loop sequences during pre-mRNA processing and to target RNase-mediated destruction of processed mRNA.

Abstract: A method for detecting movements of a plurality of points (P) of a surface (21), comprising a measuring step during which an incident ultrasonic wave is emitted into the air towards the surface and an ultrasonic wave reflected into the air by the surface (21) is detected. During the measuring step, each measuring point is illuminated by the incident ultrasonic wave at a multiplicity of angles of incidence, and the reflected ultrasonic wave is detected by a network of receiving transducers (3) comprising a plurality of ultrasonic receiving transducers (3a). The movements of the surface are determined at a measuring point by determining a delay and/or a phase shift between two beam-forming signals for said measuring point.

Abstract: The present invention relates to new N1- and N7-substituted sibiriline derivatives of the following general formula (I): (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as drug, in particular for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising such a compound and processes to prepare such a compound. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Abstract: The compound according to the invention is a compound of formula (1) Ax W1-yMOyO3, wherein A is chosen from the group comprising the Li, Na, NH4, K and H cations, and it is characterized in that x and y verify the relationships 0?x?1 and 0?y?0.5, and in that it has a crystalline structure of the hexagonal type with a base of WO6 octahedra, said structure having tunnels delimited by 6, 4 and 3 of said octahedra and oriented along the axis c.

Abstract: A mechatronic device includes two arms extending from a base in a first direction and shaped to be handheld by an operator, the two arms having free ends forming a gripper and arranged to move closer together by rotation from a rest position to an active position, a motor housed in the base, an actuator mounted between the arms, and a means for controlling said actuator, the actuator connected to the motor so as to be driven in movement in translation in the first direction. The actuator also has a first contact surface that forms a cam with a respective second contact surface on each arm, the first contact surface remaining engaged with the second contact surface. The control means controls the movement in translation of the actuator to produce a movement in rotation of the arms that applies a chosen force of the gripper in its active position.

Abstract: A multi-spectral photodetector is provided, comprising: a plurality of N photodetectors where N is an integer such that N?2, each photodetector comprising an anode and a cathode separated from one another by a region of interest, all produced in a semiconductor material; at least one electrical contact for all of the N anodes; and an electrical contact associated with each of the N cathodes; said photodetectors being stacked on top of one another such that the anodes and the cathodes and finally the regions of interest of two consecutive photodetectors in the stack are arranged face to face, this stack making it possible to define a face, termed the active face of the multi-spectral photodetector, common to all the photodetectors of the stack, defined by the face of the first region of interest of the first photodetector of the stack via which photons are intended to enter the stack.